Published in Infect Immun on April 01, 1996
Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun (1997) 2.05
Oral microbial ecology and the role of salivary immunoglobulin A. Microbiol Mol Biol Rev (1998) 1.81
Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun (1998) 1.67
Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol (1998) 1.48
Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun (2001) 1.31
Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect Immun (1998) 1.29
Differential kinetics and distribution of antibodies in serum and nasal and vaginal secretions after nasal and oral vaccination of humans. Infect Immun (1998) 1.20
Intranasal immunization with heat-inactivated Streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun (1999) 1.18
Vaccines against gonorrhea: current status and future challenges. Vaccine (2013) 1.10
M cell-targeted DNA vaccination. Proc Natl Acad Sci U S A (2001) 1.10
Elimination of Schistosoma mansoni Adult Worms by Rhesus Macaques: Basis for a Therapeutic Vaccine? PLoS Negl Trop Dis (2008) 1.08
Systemic and mucosal immune responses in mice after mucosal immunization with group B streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate vaccine. Infect Immun (2000) 1.07
Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes. Infect Immun (2004) 1.07
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol (2006) 1.06
Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun (1999) 1.02
Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria. Clin Diagn Lab Immunol (2000) 1.02
Oral immunization with the saliva-binding region of Streptococcus mutans AgI/II genetically coupled to the cholera toxin B subunit elicits T-helper-cell responses in gut-associated lymphoid tissues. Infect Immun (1997) 1.00
Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles. J Virol (2005) 1.00
Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice. Infect Immun (2005) 0.99
Generation of female genital tract antibody responses by local or central (common) mucosal immunization. Infect Immun (2000) 0.95
Anticarrier immunity suppresses the antibody response to polysaccharide antigens after intranasal immunization with the polysaccharide-protein conjugate. Infect Immun (1997) 0.94
Immunogenicity of gonococcal transferrin binding proteins during natural infections. Infect Immun (2004) 0.93
Enhanced protective antibody responses to PspA after intranasal or subcutaneous injections of PspA genetically fused to granulocyte-macrophage colony-stimulating factor or interleukin-2. Infect Immun (1998) 0.92
Monoclonal antibody-mediated modulation of the humoral immune response against mucosally applied Streptococcus mutans. Infect Immun (2000) 0.89
Chimeric plant virus particles administered nasally or orally induce systemic and mucosal immune responses in mice. J Virol (1999) 0.89
Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. J Virol (2003) 0.88
Intranasal immunization of mice with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal infection. Infect Immun (2004) 0.87
Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun (2000) 0.86
Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein. Immunology (2005) 0.83
Intranasal immunization against dental caries with a Streptococcus mutans-enriched fimbrial preparation. Clin Diagn Lab Immunol (1999) 0.83
Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology (2007) 0.83
Refocusing of B-cell responses following a single amino acid substitution in an antigen. Immunology (2001) 0.83
Intranasal immunisation with recombinant Toxoplasma gondii actin partly protects mice against toxoplasmosis. PLoS One (2013) 0.81
Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin. Immunology (1999) 0.81
A controlled clinical study of the effect of nasal immunization with a Streptococcus mutans antigen alone or incorporated into liposomes on induction of immune responses. Infect Immun (1999) 0.79
Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis. Infect Immun (2000) 0.78
Tonsillar application of formalin-killed cells of Streptococcus sobrinus reduces experimental dental caries in rabbits. Infect Immun (1999) 0.78
Characterization of antigen-presenting cells induced by intragastric immunization with recombinant chimeric immunogens constructed from Streptococcus mutans AgI/II and type I or type II heat-labile enterotoxins. Mol Oral Microbiol (2011) 0.78
Identification and characterization of intestinal antigen-presenting cells involved in uptake and processing of a nontoxic recombinant chimeric mucosal immunogen based on cholera toxin using imaging flow cytometry. Clin Vaccine Immunol (2013) 0.77
Formulation of a dry powder influenza vaccine for nasal delivery. AAPS PharmSciTech (2017) 0.76
Stone age diseases and modern AIDS. Virol J (2008) 0.75
The design of new adjuvants for mucosal immunity to Neisseria meningitidis B in nasally primed neonatal mice for adult immune response. ScientificWorldJournal (2012) 0.75
Repeated oronasal exposure to lipopolysaccharide induced mucosal IgA responses in periparturient dairy cows. PLoS One (2014) 0.75
The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol (1987) 5.30
Protein antigens of Streptococcus mutans: purification and properties of a double antigen and its protease-resistant component. Infect Immun (1980) 4.36
The role of nasopharyngeal lymphoid tissue. Immunol Today (1992) 3.19
Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. N Engl J Med (1971) 3.13
Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol (1995) 2.87
Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun (1989) 2.74
Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun (1993) 2.58
IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A (1987) 2.37
Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine (1993) 2.37
Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol (1984) 2.32
Local antibody response to poliovaccine in the human female genital tract. J Immunol (1973) 2.30
Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci. Infect Immun (1988) 2.24
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine (1994) 1.96
A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods (1988) 1.91
Combined oral/nasal immunization protects mice from Sendai virus infection. J Immunol (1987) 1.90
Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol (1995) 1.89
Protection against vaginal SIV transmission with microencapsulated vaccine. Science (1993) 1.86
Antibody-producing cells in peripheral blood and salivary glands after oral cholera vaccination of humans. Infect Immun (1991) 1.82
Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi. J Infect Dis (1986) 1.77
Induction of mucosal and systemic immunity to a recombinant simian immunodeficiency viral protein. Science (1992) 1.69
Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A (1994) 1.66
Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine (1990) 1.62
Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit. Infect Immun (1991) 1.56
Induction of compartmentalized B-cell responses in human tonsils. Infect Immun (1995) 1.54
Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J Clin Microbiol (1987) 1.53
Safety and immunogenicity of an oral recombinant cholera B subunit-whole cell vaccine in Swedish volunteers. Vaccine (1992) 1.49
Long-term cholera antitoxin memory in the gut can be triggered to antibody formation associated with protection within hours of an oral challenge immunization. Scand J Immunol (1987) 1.45
Cholera toxin and its subunits as potential oral adjuvants. Curr Top Microbiol Immunol (1989) 1.43
Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol (1994) 1.34
Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein. Infect Immun (1990) 1.32
Assay of human IgA subclass antibodies in serum and secretions by means of monoclonal antibodies. J Immunol Methods (1986) 1.32
Secretory immune responses in mouse vaginal fluid after pelvic, parenteral or vaginal immunization. Immunology (1990) 1.25
Selective transport of IgA. Cellular and molecular aspects. Gastroenterol Clin North Am (1991) 1.25
Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin. Infect Immun (1993) 1.25
Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin Exp Immunol (1992) 1.16
Targeted lymph node immunization with simian immunodeficiency virus p27 antigen to elicit genital, rectal, and urinary immune responses in nonhuman primates. J Immunol (1994) 1.13
Technical report: results of immunological tests on faecal extracts are likely to be extremely misleading. Clin Exp Immunol (1995) 1.12
Human circulating specific antibody-forming cells after systemic and mucosal immunizations: differential homing commitments and cell surface differentiation markers. Eur J Immunol (1995) 1.07
Immune response of the female rat genital tract after oral and local immunization with keyhole limpet hemocyanin conjugated to the cholera toxin B subunit. Infect Immun (1993) 1.06
Intranasal immunization of mice with recombinant protein antigen of serotype c Streptococcus mutans and cholera toxin B subunit. Arch Oral Biol (1990) 1.04
The early cellular and humoral immune response to primary and booster oral immunization with cholera toxin B subunit. Eur J Immunol (1991) 1.03
Immunology and immunopathology of tonsils. Adv Otorhinolaryngol (1992) 1.00
Local synthesis of IgG antibodies to HIV within the female and male genital tracts during asymptomatic and pre-AIDS stages of HIV infection. AIDS Res Hum Retroviruses (1995) 1.00
Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine (1994) 0.96
Effects of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin. Vaccine (1994) 0.96
Ageing compromises gastrointestinal mucosal immune response in the rhesus monkey. Immunology (1992) 0.95
Mucosal and systemic antibody formation in the rat after intranasal administration of three different antigens. Immunol Cell Biol (1991) 0.93
Estimation of the intravascular half-lives of normal rhesus monkey IgG, IgA and IgM. Immunology (1979) 0.92
Nonolfactory surface epithelium of the nasal cavity of the bonnet monkey: a morphologic and morphometric study of the transitional and respiratory epithelium. Am J Anat (1987) 0.92
Compartmentalization within the common mucosal immune system. Adv Exp Med Biol (1995) 0.89
The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histochemical study. Reg Immunol (1993) 0.88
Effect of uterine immunization and oestradiol on specific IgA and IgG antibodies in uterine, vaginal and salivary secretions. Immunology (1989) 0.88
Immunocompetent cells of the upper airway: functions in normal and diseased mucosa. Eur Arch Otorhinolaryngol (1995) 0.81
Organization of lymphoid tissue in the tonsilla lingualis. An ultrastructural study in Macaca fascicularis (Primates, Cercopithecoidea). Cell Tissue Res (1985) 0.81
Oral immunization studies with Streptococcus mutans and influenza vaccines in rhesus macaque monkeys. Adv Exp Med Biol (1995) 0.79
Estradiol regulation of secretory component: expression by rat uterine epithelial cells. J Steroid Biochem Mol Biol (1993) 0.79
The common mucosal immune system and current strategies for induction of immune responses in external secretions. J Clin Immunol (1987) 5.30
Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol (1987) 4.53
The mucosal immune system: from fundamental concepts to vaccine development. Vaccine (1992) 3.99
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int (2007) 3.17
Antibodies to native and denatured collagens in sera of patients with rheumatoid arthritis. Arthritis Rheum (1976) 2.97
Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity. Science (1976) 2.78
Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest (1999) 2.77
Selective induction of an immune response in human external secretions by ingestion of bacterial antigen. J Clin Invest (1978) 2.64
Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J Virol (1998) 2.63
Pathogenic species of the genus Haemophilus and Streptococcus pneumoniae produce immunoglobulin A1 protease. Infect Immun (1979) 2.57
Defense mechanisms involving Fc-dependent functions of immunoglobulin A and their subversion by bacterial immunoglobulin A proteases. Microbiol Rev (1988) 2.50
IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc Natl Acad Sci U S A (1987) 2.37
Secretory component of epithelial cells is a surface receptor for polymeric immunoglobulins. J Exp Med (1978) 2.26
IgA1 proteases from Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis, and Streptococcus sanguis: comparative immunochemical studies. J Immunol (1980) 2.23
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
Immunoglobulin M and secretory immunoglobulin A: presence of a common polypeptide chain different from light chains. Science (1971) 2.03
IgA nephropathy, the most common glomerulonephritis worldwide. A neglected disease in the United States? Am J Med (1988) 2.02
Immunoglobulin A (IgA). Methods Enzymol (1985) 1.94
A novel two colour ELISPOT assay. I. Simultaneous detection of distinct types of antibody-secreting cells. J Immunol Methods (1988) 1.91
Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int (1997) 1.88
Naturally occurring secretory immunoglobulin A antibodies to Streptococcus mutans in human colostrum and saliva. Infect Immun (1976) 1.85
Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release (2001) 1.85
IgA-induced eosinophil degranulation. J Immunol (1989) 1.82
Synergistic effect of IL-4 and IFN-gamma on the expression of polymeric Ig receptor (secretory component) and IgA binding by human epithelial cells. J Immunol (1990) 1.82
Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans. J Clin Microbiol (1985) 1.80
Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues. J Immunol (1984) 1.78
Regulation of IgA synthesis and immune response by T cells and interleukins. J Clin Immunol (1989) 1.76
Murine model for evaluation of protective immunity to influenza virus. Vaccine (1993) 1.73
Tissue origins of human polymeric and monomeric IgA. J Immunol (1982) 1.73
Oral tolerance in humans. T cell but not B cell tolerance after antigen feeding. J Immunol (1994) 1.72
Circulating immune complexes and immunoglobulin A rheumatoid factor in patients with mesangial immunoglobulin A nephropathies. J Clin Invest (1986) 1.70
Characterization of antibodies to the native human collagens and to their component alpha chains in the sera and the joint fluids of patients with rheumatoid arthritis. Immunochemistry (1976) 1.67
The human IgA system: a reassessment. Clin Immunol Immunopathol (1986) 1.64
Defective galactosylation and clearance of IgA1 molecules as a possible etiopathogenic factor in IgA nephropathy. Contrib Nephrol (1993) 1.64
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues. Virology (1999) 1.63
Studies on human secretory immunoglobulin A. II. Subunit structure. J Immunol (1972) 1.62
Heterosubtypic immunity to influenza A virus infection requires B cells but not CD8+ cytotoxic T lymphocytes. J Infect Dis (2000) 1.61
Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans. J Immunol (1999) 1.60
Secretory immunoglobulin A carries oligosaccharide receptors for Escherichia coli type 1 fimbrial lectin. Infect Immun (1990) 1.60
IgA subclasses. Monogr Allergy (1986) 1.57
Immunoglobulin A subclass distribution of naturally occurring salivary antibodies to microbial antigens. Infect Immun (1985) 1.53
Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation. Clin Exp Immunol (1996) 1.51
Role of serum IgA. Hepatobiliary transport of circulating antigen. J Exp Med (1981) 1.49
Concept of the local and common mucosal immune response. Adv Exp Med Biol (1978) 1.46
Production of predominantly polymeric IgA by human peripheral blood lymphocytes stimulated in vitro with mitogens. J Exp Med (1980) 1.44
Biodegradable microspheres: vaccine delivery system for oral immunization. Curr Top Microbiol Immunol (1989) 1.44
Re-assessment of risk factors for sporadic Salmonella serotype Enteritidis infections: a case-control study in five FoodNet Sites, 2002-2003. Epidemiol Infect (2006) 1.43
Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation. AIDS Res Hum Retroviruses (1998) 1.38
Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun (1998) 1.36
Secretory immune system of the female reproductive tract: I. Immunoglobulin and secretory component-containing cells. Obstet Gynecol (1988) 1.36
Limited local and systemic antibody responses to Neisseria gonorrhoeae during uncomplicated genital infections. Infect Immun (1999) 1.36
Presence of antibodies specific to cartilage-type collagen in rheumatoid synovial tissue. Clin Exp Immunol (1975) 1.35
gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med (1996) 1.35
Properties of immunoglobulin A in serum of individuals with liver diseases and in hepatic bile. Gastroenterology (1982) 1.34
Assay of human IgA subclass antibodies in serum and secretions by means of monoclonal antibodies. J Immunol Methods (1986) 1.32
Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses. J Immunol (1990) 1.30
Properties of IgA myeloma proteins isolated rom sera of patients with the hyperviscosity syndrome. J Lab Clin Med (1977) 1.29
Immunohistochemical localization of amylase, lysozyme and immunoglobulins in the human parotid gland. Arch Oral Biol (1971) 1.28
Proportion of human colostral immunoglobulin-A molecules containing the secretory determinant. Immunology (1970) 1.28
Human colostral cells. I. Separation and characterization. Clin Exp Immunol (1979) 1.27
Secretory immunity in the female reproductive tract. Am J Reprod Immunol (1994) 1.24
Bacteroides-specific IgG and IgA subclass antibody-secreting cells isolated from chronically inflamed gingival tissues. Clin Exp Immunol (1989) 1.24
Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol (2009) 1.23
Oral immunization with influenza virus in biodegradable microspheres. J Infect Dis (1993) 1.23
IgA-associated renal diseases: antibodies to environmental antigens in sera and deposition of immunoglobulins and antigens in glomeruli. J Clin Immunol (1986) 1.22
Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid. Infect Immun (1990) 1.20
The interactions of human complement with interfacially aggregated preparations of human secretory IgA. Immunochemistry (1974) 1.19
Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy. Kidney Blood Press Res (2008) 1.18
Genital secretory immune response to chronic simian immunodeficiency virus (SIV) infection: a comparison between intravenously and genitally inoculated rhesus macaques. Clin Exp Immunol (1992) 1.16
Analysis of human IgG and IgA subclass antibody-secreting cells from localized chronic inflammatory tissue. J Immunol (1989) 1.16
A polarized human endometrial cell line that binds and transports polymeric IgA. In Vitro Cell Dev Biol Anim (1995) 1.13
Normal uterine cervix: characterization of isolated lymphocyte phenotypes and immunoglobulin secretion. Am J Reprod Immunol (1995) 1.13
In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens. Infect Dis Clin North Am (1990) 1.13
Interference of secretory immunoglobulin A with sorption of oral bacteria to hydroxyapatite. Infect Immun (1981) 1.12
Interaction of specific and innate factors of immunity: IgA enhances the antimicrobial effect of the lactoperoxidase system against Streptococcus mutans. J Immunol (1982) 1.12
Site of J chain attachment to human polymeric IgA. Proc Natl Acad Sci U S A (1974) 1.12
The origin of monomeric and polymeric forms of IgA in man. Adv Exp Med Biol (1974) 1.11
Human appendix B cells naturally express receptors for and respond to interleukin 6 with selective IgA1 and IgA2 synthesis. J Clin Invest (1991) 1.11
Heterogeneity of O-glycosylation in the hinge region of human IgA1. Mol Immunol (2000) 1.11
Presence of J chain in human lymphoid cells. Clin Exp Immunol (1980) 1.10
Secretory component: interactions with intracellular and surface immunoglobulins of human lymphoid cells. J Immunol (1979) 1.09
Molecular heterogeneity of human IgA antibodies during an immune response. Clin Exp Immunol (1992) 1.08
Preferential transport of IgA and IgA-immune complexes to bile compared with other external secretions. Mol Immunol (1982) 1.08
Rectal immunization for induction of specific antibody in the genital tract of women. J Clin Immunol (1997) 1.08